Key result
SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.
Authors
Loading...
Key points are not available for this paper at this time.
Avogaro et al. (2026) studied this question. SGLT2 inhibitors serve as foundational, disease-modifying therapies for Cardiovascular-Kidney-Metabolic syndrome requiring proactive, multidisciplinary coordination for optimal management.